Vinorelbine tartrate
- CAS No.
- 125317-39-7
- Chemical Name:
- Vinorelbine tartrate
- Synonyms
- NAVELBINE;VINORELBINE DITARTRATE;NVB;VINORELBINE BITARTRATE;c’-norvincaleukoblastine,3’,4’-didehydro-4’-dioxy-,(r-(r*,r*))-2,3-dihydroxy;Vinorelbin Tartrate;VINORELBINE TARTRATE USP STANDARD;3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartrate;(2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylicacidmethylester;KW-2307
- CBNumber:
- CB8761554
- Molecular Formula:
- C53H66N4O20
- Molecular Weight:
- 1079.11
- MOL File:
- 125317-39-7.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/4/28 15:15:04
| Melting point | 181-183°C |
|---|---|
| storage temp. | 2-8°C |
| solubility | H2O: 10 mg/mL |
| form | powder |
| color | off-white |
| Stability | Light Sensitive, Temperature Sensitive |
| InChIKey | PMDHUNWDGZSEMN-WTUOTUPFSA-N |
| CAS DataBase Reference | 125317-39-7(CAS DataBase Reference) |
Vinorelbine tartrate price More Price(2)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | V2264 | Vinorelbine ditartrate salt hydrate ≥98% (HPLC), powder | 125317-39-7 | 5MG | ₹11268.83 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR3160 | Vinorelbine Tartrate pharmaceutical secondary standard, certified reference material | 125317-39-7 | 500MG | ₹86307.73 | 2022-06-14 | Buy |
Vinorelbine tartrate Chemical Properties,Uses,Production
Chemical Properties
Pale Yellow Powder
Definition
ChEBI: The L-(+)-tartrate salt of vinorelbine.
General Description
Vinorelbine ditartrate is available in 1- and 5-mL vials at aconcentration of 10 mg/mL for IV use. It is FDA approvedfor the treatment of NSCLC. The agent has also been usedin treating metastatic breast cancer, cervical cancer, uterinecancer, and lung cancer especially in older patients or thosewith physical difficulties. Vinorelbine is the most lipophilicof the vinca alkaloids because of modifications of thecatharanthine ring system and dehydration of the piperidinering. This allows the agent to be quickly taken up into cellsincluding lung tissue where concentrations are 300-foldhigher than plasma concentrations. This is 3 to 13 timeshigher than the lung concentrations seen with vincristine.The agent is highly protein bound (80%–91%) and metabolizedby CYP3A. The major metabolite seen is the 4-Odesacetylderivative, which is equally active with the parentbut only formed in small quantities. The agent is eliminatedprimarily (33%–88%) in the bile with some appearing inthe urine (16%–30%). The elimination half-life is 27 to43 hours. The toxicities seen for vinorelbine includemyelosuppression, which is dose limiting but ceases upondiscontinuation of drug. This is most commonly seen as aneutropenia, and patient’s neutrophil count should be monitoredprior to and during therapy to decrease the chanceof infection. Additional toxicities include nausea/vomiting,elevation of liver function tests, alopecia, generalized fatigue，and inappropriate secretion of antidiuretic hormone.Neurotoxicity is seen with vinorelbine but occurs to a lesserdegree compared with other vinca alkaloids because of itsdecreased affinity for axonal microtubules.
Biological Activity
Selective mitotic microtubule antagonist that exhibits > 20 fold selectivity over axonal microtubules. Inhibits proliferation of multiple human tumor cell lines (IC 50 = 1.25 nM in HeLa cells) and blocks metaphase/anaphase transition by suppression of microtubule dynamics (IC 50 = 3.8 nM). Reduces spindle length by 29% and inhibits microtubule polymerization at micromolar concentrations.
Vinorelbine tartrate Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| BDR Pharmaceuticals International Pvt Ltd | +91-2240560560 +91-7718884418 | Maharashtra, India | 206 | 58 | Inquiry |
| Manus Aktteva | +91 (79) 6512-3395 | New Delhi, India | 581 | 34 | Inquiry |
| VINKEM LABS LTD | +91 44 27661003 | New Delhi, India | 3 | 30 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| Triveni chemicals | 08048762458 | New Delhi, India | 6093 | 58 | Inquiry |
| Hardik Onco Care | 08047642620 | Ahmedabad, India | 7 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
| Indogulf Group | 91-22-23455220 | Maharashtra, India | 249 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| BDR Pharmaceuticals International Pvt Ltd | 58 |
| Manus Aktteva | 34 |
| VINKEM LABS LTD | 30 |
| CLEARSYNTH LABS LTD. | 58 |
| A.J Chemicals | 58 |
| Pharmaffiliates Analytics and Synthetics P. Ltd | 58 |
| Triveni chemicals | 58 |
| Hardik Onco Care | 58 |
| SynZeal Research Pvt Ltd | 58 |
| Indogulf Group | 58 |